Policy / Pricing US launches probe of German ‘underpayment’ for medicines PharmaphorumA Section 301 probe by the US Trade Representative into Germany's medicine pricing and reimbursement policies raises the threat of punitive tariffs.Read full story pharminent June 19, 2026 (Last updated: June 22, 2026) Pharmaphorum A Section 301 probe by the US Trade Representative into Germany’s medicine pricing and reimbursement policies raises the threat of punitive tariffs. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Biogen to acquire RayThera for up to $1bnNext: Denali sells FDA voucher for $195M to support neurodegenerative pipeline Related Stories Policy / Pricing US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028 pharminent July 22, 2026 Policy / Pricing UK commits to pharma IP protection in Swiss trade deal pharminent July 16, 2026 Policy / Pricing Germany approves healthcare costs overhaul despite significant pharma opposition pharminent July 13, 2026
